The Baltimore-based biotech company Elixirgen Therapeutics, Inc., has reported positive results from the first two patients to receive the company’s novel treatment for telomere biology disorders.
According to findings published Feb. 25, 2025, in NEJM Evidence, the patients experienced successful sustained telomere elongation from a treatment called EXG-34217. Also, no treatment-related safety concerns were observed over a 24-month and a 5-month period, respectively.